The clinical role of procalcitonin in hematopoietic SCT

Bone Marrow Transplantation
J KoyaM Kurokawa

Abstract

Infectious disease following hematopoietic SCT (HSCT) is a major cause of TRM. The more valuable markers to distinguish infections disease from non-infectious complications are needed. Procalcitonin (PCT) and C-reactive protein (CRP) were measured periodically throughout the clinical course of consecutive 28 patients who underwent HSCT. The diagnoses of 103 febrile episodes were analyzed. PCT and CRP level on the first day of fever significantly increased in systemic bacterial or fungal infection (P<0.001 and <0.001, respectively). PCT is more valuable than CRP for discrimination between systemic bacterial or fungal infection and intracellular infection (P=0.022 and 0.447, respectively). The area under receiver-operator characteristics curve for detection of bacterial or fungal infection was 0.82 for PCT and 0.76 for CRP. When PCT levels did not increase over 0.25 ng/mL through the fifth day of fever, PCT yielded a specificity of 100.0%. In multivariate analysis, the maximum level of PCT during a whole course of HSCT>=2 ng/mL was independently associated with worse overall survival as post-transplant predictors (adjusted hazard ratio 6.42, P=0.035). PCT provide additional information for discrimination between bacterial or fung...Continue Reading

References

Nov 4, 2000·Clinical and Diagnostic Laboratory Immunology·N M BlijlevensB E De Pauw
Nov 23, 2000·Intensive Care Medicine·K ReinhartM Meisner
Mar 22, 2001·Archives of Disease in Childhood·F MoulinD Gendrel
May 22, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E J Giamarellos-BourboulisH Giamarellou
Jul 4, 2001·Bone Marrow Transplantation·T R Spitzer
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Liliana SimonJacques Lacroix
Jul 26, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Vincent T HoSergio Giralt
Apr 11, 2006·American Journal of Respiratory and Critical Care Medicine·Mirjam Christ-CrainBeat Müller
Dec 22, 2007·American Journal of Respiratory and Critical Care Medicine·Vandack NobreJérôme Pugin
May 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ben De PauwUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
May 13, 2008·Intensive Care Medicine·D Gendrel, C Bohuon
Sep 10, 2009·JAMA : the Journal of the American Medical Association·Philipp SchuetzUNKNOWN ProHOSP Study Group
Jan 25, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alison G Freifeld Infectious Diseases Society of America

❮ Previous
Next ❯

Citations

Oct 30, 2013·The Journal of Antimicrobial Chemotherapy·Lubos DrgonaJ Peter Donnelly
Feb 8, 2013·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Y-X LyuM-Y Zhu
May 15, 2012·Clinica Chimica Acta; International Journal of Clinical Chemistry·Junji KoyaMineo Kurokawa
Nov 1, 2016·Bone Marrow Transplantation·C M LucenaC Agustí
Jan 31, 2017·Journal of Clinical Laboratory Analysis·Yasuhiro EbiharaKenji Ikebuchi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.